MoonLake Immunotherapeutics says it has sent a request to the FDA to approve sonelokimab for a skin condition.

Sep 30, 2026, 4:23 PM ETTrialRead the original at SEC EDGAR

Good for MLTX

MoonLake's application filing is a positive step toward possible U.S. sales of sonelokimab. The FDA has not yet accepted it for review or approved the drug.

MLTX · MoonLake Immunotherapeutics

AI read · Good for MLTX

The AI's read

This puts sonelokimab closer to a possible U.S. launch. The FDA has not yet agreed to review the application, and approval is still undecided. The filing helps MoonLake's prospects, but does not confirm a launch or sales.

Get alerts for MLTX

Follow MoonLake Immunotherapeutics (MLTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MLTX

Free on the App Store and Google Play, or on the web.